Total Payments
$90,506
2024 Payments
$1,100
Companies
20
Transactions
109
Medicare Patients
1,590
Medicare Billing
$296,760
Payment Breakdown by Category
Research$81,767 (90.3%)
Travel$5,323 (5.9%)
Food & Beverage$2,565 (2.8%)
Consulting$850.00 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $81,767 | 45 | 90.3% |
| Travel and Lodging | $5,323 | 14 | 5.9% |
| Food and Beverage | $2,565 | 49 | 2.8% |
| Consulting Fee | $850.00 | 1 | 0.9% |
Payments by Type
Research
$81,767
45 transactions
General
$8,739
64 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $62,816 | 15 | $0 (2018) |
| LEO Pharma AS | $13,240 | 4 | $0 (2018) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,149 | 19 | $0 (2020) |
| Allergan Inc. | $1,953 | 14 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $1,822 | 11 | $0 (2017) |
| Janssen Research & Development, LLC | $1,570 | 7 | $0 (2017) |
| Corcept Therapeutics | $1,140 | 6 | $0 (2019) |
| Eisai Inc. | $1,130 | 6 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $850.00 | 1 | $0 (2024) |
| Alkermes, Inc. | $651.18 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,100 | 3 | E.R. Squibb & Sons, L.L.C. ($850.00) |
| 2023 | $34.77 | 2 | Janssen Pharmaceuticals, Inc ($21.90) |
| 2021 | $241.28 | 6 | ITI, Inc. ($118.72) |
| 2020 | $1,516 | 13 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,312) |
| 2019 | $2,849 | 17 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,363) |
| 2018 | $17,376 | 23 | LEO Pharma AS ($13,240) |
| 2017 | $67,389 | 45 | ACADIA Pharmaceuticals Inc ($60,831) |
All Payment Transactions
109 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 03/19/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neuroscience | ||||||
| 03/05/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: Psychology/Psychiatric | ||||||
| 02/10/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: PSYCHIATRY | ||||||
| 01/10/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Neuroscience | ||||||
| 11/30/2021 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY (Device) | Food and Beverage | Cash or cash equivalent | $67.83 | General |
| Category: NEUROSTAR TMS THERAPY | ||||||
| 11/11/2021 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $118.72 | General |
| Category: PSYCHIATRY | ||||||
| 10/23/2021 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $12.96 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 07/28/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: PSYCHIATRY | ||||||
| 06/05/2021 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 03/09/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2020 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 09/11/2020 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 08/27/2020 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: PSYCHIATRY | ||||||
| 07/08/2020 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: PSYCHIATRY | ||||||
| 02/22/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $324.05 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/22/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $101.32 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/22/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/22/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $565.77 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $120.00 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $101.32 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/20/2020 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $121.97 | General |
| Category: CNS | ||||||
| 01/27/2020 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $13.06 | General |
| Category: NEUROLOGY | ||||||
| 12/05/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $85.38 | General |
| Category: CNS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-034 | ACADIA Pharmaceuticals Inc | $23,698 | 4 |
| ACP-103-038 | ACADIA Pharmaceuticals Inc | $18,797 | 3 |
| ACP-103-035 | ACADIA Pharmaceuticals Inc | $15,321 | 7 |
| TRALOKINUMAB DRUG INTERACTION TRAIL | LEO Pharma AS | $13,240 | 4 |
| ACP-103-042 | ACADIA Pharmaceuticals Inc | $5,000 | 1 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,474 | 5 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,363 | 7 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,312 | 7 |
| Study 876 | Corcept Therapeutics | $1,140 | 6 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $421.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 384 | 1,022 | $151,453 | $69,030 |
| 2022 | 4 | 454 | 1,075 | $160,983 | $67,942 |
| 2021 | 3 | 338 | 979 | $145,808 | $65,260 |
| 2020 | 5 | 414 | 1,509 | $210,253 | $94,528 |
Total Patients
1,590
Total Services
4,585
Medicare Billing
$296,760
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 148 | 651 | $72,124 | $37,253 | 51.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 99 | 112 | $43,599 | $14,381 | 33.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Office | 2023 | 65 | 182 | $21,112 | $10,471 | 49.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 56 | 60 | $9,561 | $4,721 | 49.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 16 | 17 | $5,058 | $2,204 | 43.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 172 | 651 | $72,390 | $33,665 | 46.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 106 | 122 | $45,006 | $15,784 | 35.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Office | 2022 | 70 | 160 | $19,836 | $8,287 | 41.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 72 | 82 | $13,101 | $6,310 | 48.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 21 | 22 | $6,545 | $2,928 | 44.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 38 | $4,105 | $966.65 | 23.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 123 | 731 | $77,640 | $39,030 | 50.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 115 | 135 | $50,208 | $17,335 | 34.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 100 | 113 | $17,961 | $8,895 | 49.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 141 | 1,129 | $119,690 | $62,919 | 52.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2020 | 129 | 157 | $58,072 | $17,318 | 29.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 114 | 141 | $22,419 | $11,473 | 51.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 16 | 67 | $5,406 | $1,589 | 29.4% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2020 | 14 | 15 | $4,666 | $1,229 | 26.3% |
About Dr. Fayz Hudefi, MD
Dr. Fayz Hudefi, MD is a Psychiatry healthcare provider based in Fort Smith, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992740393.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Fayz Hudefi, MD has received a total of $90,506 in payments from pharmaceutical and medical device companies, with $1,100 received in 2024. These payments were reported across 109 transactions from 20 companies. The most common payment nature is "" ($81,767).
As a Medicare-enrolled provider, Hudefi has provided services to 1,590 Medicare beneficiaries, totaling 4,585 services with total Medicare billing of $296,760. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Addiction Medicine
- Location Fort Smith, AR
- Active Since 06/19/2006
- Last Updated 11/21/2022
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1992740393
Products in Payments
- NUPLAZID (Drug) $62,816
- MK-8189 (Drug) $1,822
- VRAYLAR (Drug) $1,628
- INVEGA TRINZA (Drug) $1,570
- BREXPIPRAZOLE (Drug) $1,474
- REXULTI (Drug) $1,362
- COBENFY (Drug) $850.00
- Aristada 441 mg (Drug) $324.92
- ARISTADA (Drug) $208.28
- LATUDA (Drug) $142.08
- CAPLYTA (Drug) $131.59
- SPRAVATO (Drug) $125.00
- Auvelity (Drug) $124.97
- NEUROSTAR TMS THERAPY (Device) $67.83
- HETLIOZ (Drug) $57.55
- INGREZZA (Drug) $26.66
- INVEGA SUSTENNA (Drug) $21.90
- TRINTELLIX (Drug) $15.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Fort Smith
Dr. Kevin Price, Md, MD
Psychiatry — Payments: $2,581
Psychiatry $2,581
Rachel Fiori, Md, MD
Psychiatry — Payments: $2,455
Psychiatry $2,455
Dr. Venkata Vijaya Kumar Dalai, M.d., M.p.h, M.D., M.P.H
Psychiatry — Payments: $2,085
Psychiatry $2,085
Dr. Donald Chambers, M.d, M.D
Psychiatry — Payments: $1,793
Psychiatry $1,793
Dr. William Kindrick, M.d, M.D
Psychiatry — Payments: $654.77
Psychiatry $654.77
Dr. Kristi Kindrick, M.d, M.D
Psychiatry — Payments: $454.97
Psychiatry $454.97